New hope for rare blood cancers: first human trial of PRT12396 begins
NCT ID NCT07469891
First seen Mar 20, 2026 · Last updated May 20, 2026 · Updated 8 times
Summary
This early-stage study tests a new drug called PRT12396 in about 100 people with two rare blood cancers: polycythemia vera and myelofibrosis. The main goals are to find a safe dose and see if the drug can help control the disease. Participants must have a specific genetic mutation (JAK2 V617F) and be well enough for daily activities.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA (PV) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BRCR Global - Coral Springs
RECRUITINGCoral Springs, Florida, 33065, United States
-
START Midwest, LLC
RECRUITINGGrand Rapids, Michigan, 49546, United States
Conditions
Explore the condition pages connected to this study.